Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Topamax Letter Recommends Monitoring For Decreased Sweating

Executive Summary

A warning added to Johnson & Johnson's anti-convulsant Topamax (topiramate) is in line with a label revision for Elan's anti-convulsant Zonegran stating that patients should be closely monitored for decreased sweating and increased body temperature

You may also be interested in...



Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children

FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information

Topamax Draws FDA Warning Letter For Promoting Unsafe Use In Children

FDA is citing Johnson & Johnson's Topamax for a website and sales aid that lack sufficient safety information

J&J Topamax “Dear Doctor” Letter Advises Metabolic Acidosis Monitoring

Physicians should periodically examine Topamax (topiramate) patients for metabolic acidosis, a Johnson & Johnson "Dear Health Care Professional" letter recommends

Related Content

UsernamePublicRestriction

Register

PS042134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel